Disclosure: See original article for full disclosure list.

1. Ciampi de Andrade D, Rodrigues CL, Abraham R, et al. Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study. Neurology 2010;74:1288–1295.
2. Bianchin MM, Velasco TR, Takayanagui OM, Sakamoto AC. Neurocysticercosis, mesial temporal lobe epilepsy, and hippocampal sclerosis: an association largely ignored. Lancet Neurol 2006;5:20–21.
3. Hoek RM, van Kesteren RE, Smit AB, de Jong-Brink M, Geraerts WP. Altered gene expression in the host brain caused by a trematode parasite: neuropeptide genes are preferentially affected during parasitosis. Proc Natl Acad Sci USA 1997;94:14072–14076.
4. Vyas A, Kim SK, Giacomini N, Boothroyd JC, Sapolsky RM. Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc Natl Acad Sci USA 2007;104:6442–447.
5. Morales-Montor J, Arrieta I, Del Castillo LI, Rodríguez-Dorantes M, Cerbón MA, Larralde C. Remote sensing of intraperitoneal parasitism by the host's brain: regional changes of c-fos gene expression in the brain of feminized cysticercotic male mice. Parasitology 2004;128:343–351.

CORRECTION

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

In the article "A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis" by J.M. Burton et al. (*Neurology*® 2010;74:1852–1859), in figure 2, panels A, C, and D, the vitamin D3 dose was incorrectly labeled. The corrected figure is reprinted below. The editorial staff regrets the error.

Figure 2 Serum calcium and 25(OH)D results within and between patients



(A) Mean serum calcium (mmol/L) over dosing regimen in treatment group. (B) Mean serum calcium (mmol/L) of control and treatment groups at week 1 (0 IU/day vitamin D3 for treatment group), week (10,000 IU/day of vitamin D3 for treatment group), week (40,000 IU/day of vitamin D3 for treatment group), and week (discontinuation of vitamin D3 for treatment group). (C) Urinary calcium: creatinine ratios over dosing regimen in treatment group. (D) Serum 25(OH)D (nmol/L) over dosing regimen in treatment group [the value on the y-axis reflects the mean 25(OH)D level after completing the course associated with the dose of vitamin D on the x-axis].